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Background/aim: Sleep disturbances may contribute to poor treatment outcomes in opioid-dependent patients. The extent to which
the sleep profiles of opioid-dependent patients differ from those of the general Malaysian population is not documented. This study
compared opioid-naive subjects and opioid-dependent patients on methadone maintenance therapy (MMT) in terms of their sleep
quality.
Materials and methods: Participants comprised Malay male opioid-naive subjects (n = 159) and opioid-dependent patients (n = 160)
from MMT clinics in Kelantan, Malaysia, between March and October 2013. Sleep quality was evaluated using the translated and
validated Malay version of the Pittsburgh Sleep Quality Index (PSQI).
Results: The opioid-dependent patients exhibited higher global PSQI scores [adjusted mean (95% CI) = 5.46 (5.02, 5.90)] than the
opioid-naive group [4.71 (4.26, 5.15)] [F (1, 313) = 4.77, P = 0.030].
Conclusion: This study confirmed the poorer sleep quality among opioid-dependent patients on MMT, as manifested by their higher
global PSQI scores. The sleep complaints in this patient population are a factor to consider and, when necessary, sleep evaluation and
treatment should be undertaken to improve MMT patients’ quality of sleep and overall treatment outcome.
Key words: Clinical, insomnia, methadone, outcomes, response, subjective, sleep, sleep quality

1. Introduction
Worldwide, the problem of opioid dependence is growing
and has become an important public health concern. This
growing group of patients has extensive health care needs
and management of opioid dependence represents a great
challenge to clinicians. Although methadone is available,
discontinuation of methadone maintenance therapy
(MMT) and continued use of opiates pose challenges to
the treatment of patients with opiate dependence.
In addition to comorbid medical and psychiatric
illnesses such as pain and depression, sleep disturbance
may also contribute to poor treatment outcome in opioiddependent patients. Previous studies have shown that sleep
disturbances caused premature exit from treatment (1–3),
increased use of sleep medications (4–6), and increased
chronic depressive symptoms (7,8). Evidence also showed
that sleep disturbances affected patients’ quality of life
* Correspondence: zzalina@usm.my

and impaired their engagement with treatment, leading
to continue illicit drug use (4,7,9). Opioid-dependent
patients frequently reported sleep problems during MMT
(4–6,8–12). However, physicians often underestimate the
sleep complaints in this patient population.
Several papers on sleep quality in opioid-dependent
patients during MMT were published previously in the
United States and other countries (4–6,12–16). However,
sleep disorder data are largely unavailable in Malaysia. A
previous study used the Pittsburgh Sleep Quality Index
(PSQI) to investigate the effects of electroacupuncture
on sleep quality in 20 patients receiving MMT in Kajang,
Malaysia (17). Recently, we published our data on the
relationship between cold pressor pain-sensitivity and
sleep quality in opioid-dependent males on methadone
treatment (18); however, the distinct sleep component
of patients on MMT in comparison with the data from
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a sample of opioid-naive individuals has not been
characterized. In the absence of published data in our local
population that document the extent to which the sleep
profiles of opioid-dependent patients differ from those
of the general population, clinical studies may provide
important information regarding sleep quality in these
patients. This study sought to fill this gap.
The present study investigated sleep quality using
the translated and validated Malay language version of
the PSQI in opioid-naive subjects and opioid-dependent
patients on MMT to test the hypothesis that there is a
significant difference in sleep quality between this patient
population and the general population.
2. Materials and methods
2.1. Participants
This observational cross-sectional study involved Malay
male subjects ≥18 years of age. Participants comprised
opioid-naive subjects (n = 159) and opioid-dependent
patients (n = 160) according to the DSM-IV criteria
(19). We selected only Malay male subjects in this study,
trying to minimize the influence of ethnicity on sleep
quality (20,21) and because drug abusers in Malaysia
are predominantly males; thus, this reflects our patient
population (22). Participants were recruited from March
to October 2013 as part of an ongoing clinical study
to evaluate the application of personalized methadone
therapy among patients on MMT.
Opioid-naive subjects were defined as individuals
who had not taken any opioids including morphine and
methadone to their best knowledge and were presumed
so after two consecutive negative urine screenings for
drugs. They were recruited from the local and university
communities via word of mouth. Subjects with acute or
chronic medical, surgical, and psychiatric illnesses that
required medical, surgical, or psychiatric therapy were
excluded from the study.
Opioid-dependent patients met the inclusion and
exclusion criteria of the national MMT program and
were currently enrolled in the national MMT program at
Hospital Universiti Sains Malaysia and other MMT clinics
in Kelantan. All were stabilized in treatment, defined
as having been enrolled in the program for more than
1 month with no change of methadone dosage over the
past 1 month. Patients with acute medical, surgical, and
psychiatric illnesses and those acutely intoxicated were
excluded. Patients who had major psychiatric illness,
peripheral vascular disease, chronic or ongoing acute
pain, or benzodiazepine, cannabinoid, and barbiturate
abuse; those on regular anticonvulsants, neuroleptics, or
analgesics; and those who used alcohol regularly were also
excluded from the study.
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As we found that the number of available opioidnaive subjects and patients receiving MMT who met all
inclusion and exclusion criteria were limited, we took all
eligible subjects within the study period.
2.2. Data collection
Each subject was informed about the nature and purpose
of the study and the usage of data, and was asked if he
would participate. If he agreed, written informed consent
was obtained. Subjects were then asked to fill out the
translated and validated Malay version of the PSQI.
The PSQI is one of the validated self-administered
written questionnaires to measure subjective sleep quality
and disturbances during the previous month and to
discriminate between ‘good’ and ‘poor’ sleepers that has
been translated into several languages, including Malay.
The Malay translation of this questionnaire was performed
by the MAPI Research Trust and permission for use the
Malay version of the PSQI was obtained from its authors
at the University of Pittsburgh (23).
The PSQI contains 19 items that are included in
scoring. The 19 individual items are used to generate seven
component scores: subjective sleep quality (one item), sleep
latency (two items), sleep duration (one item), habitual
sleep efficiency (three items), sleep disturbances (nine
items), use of sleep medications (one item), and daytime
dysfunction (two items). Each of the seven component
scores is determined based on scoring guidelines, with
the seven component scores each with a potential range
of 0–3, where 3 reflects the negative extreme on the
Likert scale. The sum of these seven component scores
yields one global score of subjective sleep quality with a
potential range of 0–21, with higher scores representing
poorer subjective sleep quality. A global PSQI score of >5,
as we used, indicates that an individual has severe sleep
difficulties in at least two areas or moderate difficulties in
more than three areas (23). The internal consistency and
reliability of the PSQI as estimated by Cronbach’s alpha
was 0.83 (23).
2.3. Ethics
The study was approved by the Human Research Ethics
Committee of Universiti Sains Malaysia in Kelantan,
Malaysia, (reference number: USMKK/PPP/JEPeM (253.3
[14]), and the Medical Research & Ethics Committee,
Ministry of Health, Malaysia (reference number: NMRR13-524-16614).
2.4. Statistical analysis
Frequency and percentages were computed for categorical
variables, and for numerical variables, mean and standard
deviation (SD) were also computed. Comparison of the PSQI
data between opioid-naive individuals and the MMT group
were evaluated using an independent t-test. We studied sleep
disorders as a continuous variable (the global PSQI scores).
The independent t-test was used to compare factors that
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may affect sleep quality such as age and body mass index
(BMI) between opioid-naive and MMT groups. Analysis of
covariance (ANCOVA) was carried out to further elucidate
the mean difference of the global PSQI scores between the
opioid-naive and MMT groups taking other covariates
such as age and BMI. All analyses were done using SPSS for
Windows (version 20, IBM Corp., Armonk, NY, USA). P <
0.05 was considered significant.
3. Results
Opioid-naive subjects averaged 27.6 (SD 10.12) years of
age, ranging from 18 to 63 years old. The mean BMI of
these subjects was 24.8 (SD 5.31), ranging from 15.0 to
45.0 kg/m2. Patients averaged 37.2 (SD 6.19) years of age,
ranging from 25 to 55 years old. The mean BMI of these
patients was 22.2 (SD 3.65), ranging from 14.9 to 36.3 kg/
m2. The mean age and BMI were significantly different
between the opioid-naive and MMT groups (P < 0.001).
3.1. PSQI data in opioid-naive and opioid-dependent
subjects
The PSQI data in opioid-naive and opioid-dependent
subjects are presented in Table 1. The mean global PSQI
score was 5.43 (SD 2.75), slightly above a cut-off score
of 5, thus indicating poor overall sleep quality among
patients. The mean global PSQI score of opioid-naive
subjects was 4.74 (SD 2.30), indicating good overall sleep
quality. The mean global PSQI score was significantly
different between the opioid-naive and MMT groups (P <
0.016). More specifically, 40.0% (n = 64) of patients were

identified as ‘poor sleepers’ (global PSQI scores >5), and
49 (30.8%) of opioid-naive subjects had PSQI scores of >5,
but the difference did not reach statistical significance [χ2
(df) = 2.94 (1), P = 0.086].
3.2. Comparison of global PSQI scores between opioidnaive and opioid-dependent subjects
The analysis of covariance revealed that opioid-dependent
patients had higher global PSQI scores [adjusted mean
(95% CI) = 5.46 (5.02, 5.90)] than the opioid-naive group
[4.71 (4.26, 5.15)] [F (1, 313) = 4.77, P = 0.030] (Table 2).
4. Discussion
The present study investigated sleep quality in opioidnaive Malay subjects and opioid-dependent Malay
patients on MMT. An important finding of this study is
that the sleep quality is significantly different between this
patient population and opioid-naive subjects. Compared
with opioid-naive subjects, opioid-dependent patients
had significantly higher sleep latency scores, lower sleep
duration scores, higher sleep disturbance scores, higher
use of sleep medication scores, and higher daytime
dysfunction scores.
Though several reports on the severity and prevalence of
sleep disorders in patients receiving MMT were previously
published, this study is important because it identifies the
sleep problems in patients on MMT in comparison with
the data from a sample of opioid-naive individuals, which
has largely been unstudied. Furthermore, this study was
designed to exclude patients with chronic medical and

Table 1. The PSQI components, global PSQI, and other sleep variables reported by opioid-naive controls and opioid-dependent patients.
Mean (SD)

Variable

Opioid-naive (N = 159)

Patient (N = 160)

Test stat. (df) a

P-value

Component scores
1.

Subjective sleep quality

0.79 (0.58)

0.86 (0.52)

–1.24 (313)

0.216

2.

Sleep latency

0.89 (0.82)

1.14 (0.70)

–2.95 (309)

0.003

3.

Sleep duration

0.75 (0.94)

0.51 (0.83)

2.37 (312)

0.018

4.

Habitual sleep efficiency

0.19 (0.56)

0.30 (0.74)

–1.51 (297)

0.133

5.

Sleep disturbances

1.11 (0.48)

1.30 (0.63)

–2.98 (296)

0.003

6.

Use of sleep medication

0.18 (0.46)

0.33 (0.78)

–2.18 (258)

0.030

7.

Daytime dysfunction

0.84 (0.65)

0.98 (0.61)

–2.06 (316)

0.040

Global PSQI

4.74 (2.30)

5.43 (2.75)

–2.43 (308)

0.016

Minutes to fall asleep

17.02 (17.33)

21.74 (15.00)

–2.61 (317)

0.010

Actual sleep time per night (h)

6.78 (1.63)

7.23 (1.61)

–2.45 (317)

0.015

Significant P-values are in bold; a t-statistic using independent t-test.
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Table 2. Comparison of global PSQI scores between opioid-naive controls and opioid-dependent patients controlling for potential
confounders.
Group

Adj. meana (95% CI)

Adj. mean diff. (95% CI)b

F stat. (df)

P-valuec

Opioid-naive (N = 159)

4.71 (4.26, 5.15)

-0.75 (-1.43, -0.08)

4.77 (1, 313)

0.030

Patient (N = 160)

5.46 (5.02, 5.90)

CI, Confidence interval.
a
Adjusted mean controlling for age and BMI; b Bonferroni adjustment for 95% confidence interval for difference; c P-values were obtained
using analysis of covariance.

psychiatric illnesses such as chronic pain, depression, and
anxiety that are associated with sleep disorders. We think
that these findings may provide important information
regarding sleep quality in this patient population.
Malay patients have significantly higher global PSQI
scores compared with the opioid-naive subjects. Previously,
Xiao et al. designed a study to explore the nocturnal sleep
structure of patients on early methadone treatment in
Beijing, China (24). They evaluated subjective sleep using
the PSQI and the Epworth Sleepiness Scale. They also
assessed objective sleep patterns with overnight limited
polysomnography (PSG). They showed that patients in
early methadone treatment had poor sleep quality and
abnormal sleep architecture. They similarly found that the
PSQI scores among 20 male patients on early methadone
treatment (mean (SD) = 10.5 (4.4)) were significantly
higher than those of 20 healthy male controls [mean (SD)
= 3.6 (1.8)) (t (df) = 6.92 (38), P ≤ 0.001].
Results of PSG showed that patients had lower sleep
efficiency, shorter total sleep time, more awakenings, and
shorter slow wave sleep compared with healthy controls.
Similarly, we found that the patients had lower sleep
duration scores than opioid-naive subjects. In contrast,
habitual sleep efficiency score was higher (but not
statistically significant) in patients compared to opioidnaive individuals.
Oyefeso et al. investigated subjective sleep parameters
and sleep difficulties of opiate addicts undertaking
methadone detoxification using the St. Mary’s Hospital
Sleep Questionnaire (3). They found that the subjective
sleep parameters of opiate addicts undertaking inpatient methadone detoxification (n = 27, 16 males and
11 females) were quantitatively and qualitatively different
compared with those of drug-free controls (n = 26, 9 males
and 17 females).
Compared with healthy controls, patients reported
significantly shorter nocturnal sleep, longer sleep onset
latency, and greater difficulty falling asleep. Similarly, we
found that patients had lower sleep duration scores, higher
sleep latency scores, and longer time to fall asleep.
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Wang et al. studied sleep problems in patients on MMT.
In both studies, MMT patients (n = 50, 25 males and 25
females) and 20 normal subjects underwent PSG (8,25).
Patients demonstrated shorter total sleep time, higher
sleep efficiency, and lower sleep onset latency compared to
age-, sex-, and BMI-matched normal subjects. However,
the differences were not statistically significant.
In the study by Wang et al., participants completed
standardized questionnaires including the Epworth
Sleepiness Scale and Functional Outcome of Sleep
Questionnaire (8). They found that patients receiving
MMT had significantly worse daytime function and had
increased daytime sleepiness when compared with control
subjects. Similarly, our patients had higher daytime
dysfunction scores compared to opioid-naive subjects.
Almost all previous studies reported significant
differences in sleep quality between opioid-dependent
patients on MMT and opioid-naive subjects. In terms of
the global PSQI, our current study confirmed the results
of an earlier study (24) in that it showed the poorer sleep
quality among opioid-dependent patients on MMT
compared to the general population.
As with all studies, this study has limitations such as the
lack of objective sleep evaluation. PSG could have helped
as it objectively measures sleep quality, latency, duration,
and habitual sleep efficiency that are subjectively covered
by the PSQI, in addition to other parameters, such as sleep
architecture (15). This was not available for our work.
Second, we did not included both sexes in our study and
only male subjects were included, as this reflects the cohort
population of drug abusers in Malaysia, where more than
90% of them are male (22). Third, the sleep quality data are
cross-sectional in nature, and therefore the current study
cannot address the effects of MMT on sleep.
Notwithstanding these limitations, this study confirmed
the poorer sleep quality among opioid-dependent patients
on MMT, as manifested by their higher global PSQI scores.
Data on the sleep quality in a sample of patients on MMT
will hopefully provide complementary information and
allow better prescription of methadone for individual
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subjects in close association with drug efficacy and adverse
drug reactions observed in each subject. Therefore, the
sleep complaints in this patient population should not be
underestimated. Sleep evaluation and treatment should
be done to improve MMT patients’ quality of sleep and
overall treatment outcome.
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